Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users

Chandni Hindocha, Tom P Freeman, Grainne Schafer, Chelsea Gardener, Ravi K Das, Celia J A Morgan, H Valerie Curran

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Acute administration of the primary psychoactive constituent of cannabis, Δ-9-tetrahydrocannabinol (THC), impairs human facial affect recognition, implicating the endocannabinoid system in emotional processing. Another main constituent of cannabis, cannabidiol (CBD), has seemingly opposite functional effects on the brain. This study aimed to determine the effects of THC and CBD, both alone and in combination on emotional facial affect recognition. 48 volunteers, selected for high and low frequency of cannabis use and schizotypy, were administered, THC (8mg), CBD (16mg), THC+CBD (8mg+16mg) and placebo, by inhalation, in a 4-way, double-blind, placebo-controlled crossover design. They completed an emotional facial affect recognition task including fearful, angry, happy, sad, surprise and disgust faces varying in intensity from 20% to 100%. A visual analogue scale (VAS) of feeling 'stoned' was also completed. In comparison to placebo, CBD improved emotional facial affect recognition at 60% emotional intensity; THC was detrimental to the recognition of ambiguous faces of 40% intensity. The combination of THC+CBD produced no impairment. Relative to placebo, both THC alone and combined THC+CBD equally increased feelings of being 'stoned'. CBD did not influence feelings of 'stoned'. No effects of frequency of use or schizotypy were found. In conclusion, CBD improves recognition of emotional facial affect and attenuates the impairment induced by THC. This is the first human study examining the effects of different cannabinoids on emotional processing. It provides preliminary evidence that different pharmacological agents acting upon the endocannabinoid system can both improve and impair recognition of emotional faces.

LanguageEnglish
Pages325-334
Number of pages10
JournalEuropean Neuropsychopharmacology
Volume25
Issue number3
Early online date5 Dec 2014
DOIs
StatusPublished - 1 Mar 2015

Fingerprint

Cannabidiol
Dronabinol
Cannabis
Emotions
Placebos
Endocannabinoids
Cannabinoids
tetrahydrocannabinol-cannabidiol combination
Visual Analog Scale
Cross-Over Studies
Inhalation
Volunteers
Pharmacology

Keywords

  • Administration, Inhalation
  • Cannabidiol/pharmacology
  • Cross-Over Studies
  • Double-Blind Method
  • Dronabinol/pharmacology
  • Drug Combinations
  • Drug Interactions
  • Emotions/drug effects
  • Facial Recognition/drug effects
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Marijuana Smoking/drug therapy
  • Photic Stimulation
  • Psychotropic Drugs/pharmacology
  • Schizotypal Personality Disorder/chemically induced
  • Surveys and Questionnaires
  • Visual Analog Scale
  • Young Adult

Cite this

Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition : a randomised, double-blind, placebo-controlled study in cannabis users. / Hindocha, Chandni; Freeman, Tom P; Schafer, Grainne; Gardener, Chelsea; Das, Ravi K; Morgan, Celia J A; Curran, H Valerie.

In: European Neuropsychopharmacology, Vol. 25, No. 3, 01.03.2015, p. 325-334.

Research output: Contribution to journalArticle

Hindocha, Chandni ; Freeman, Tom P ; Schafer, Grainne ; Gardener, Chelsea ; Das, Ravi K ; Morgan, Celia J A ; Curran, H Valerie. / Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition : a randomised, double-blind, placebo-controlled study in cannabis users. In: European Neuropsychopharmacology. 2015 ; Vol. 25, No. 3. pp. 325-334.
@article{34d34c2ab2794a55b8c0a4b4d3c1ea29,
title = "Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users",
abstract = "Acute administration of the primary psychoactive constituent of cannabis, Δ-9-tetrahydrocannabinol (THC), impairs human facial affect recognition, implicating the endocannabinoid system in emotional processing. Another main constituent of cannabis, cannabidiol (CBD), has seemingly opposite functional effects on the brain. This study aimed to determine the effects of THC and CBD, both alone and in combination on emotional facial affect recognition. 48 volunteers, selected for high and low frequency of cannabis use and schizotypy, were administered, THC (8mg), CBD (16mg), THC+CBD (8mg+16mg) and placebo, by inhalation, in a 4-way, double-blind, placebo-controlled crossover design. They completed an emotional facial affect recognition task including fearful, angry, happy, sad, surprise and disgust faces varying in intensity from 20{\%} to 100{\%}. A visual analogue scale (VAS) of feeling 'stoned' was also completed. In comparison to placebo, CBD improved emotional facial affect recognition at 60{\%} emotional intensity; THC was detrimental to the recognition of ambiguous faces of 40{\%} intensity. The combination of THC+CBD produced no impairment. Relative to placebo, both THC alone and combined THC+CBD equally increased feelings of being 'stoned'. CBD did not influence feelings of 'stoned'. No effects of frequency of use or schizotypy were found. In conclusion, CBD improves recognition of emotional facial affect and attenuates the impairment induced by THC. This is the first human study examining the effects of different cannabinoids on emotional processing. It provides preliminary evidence that different pharmacological agents acting upon the endocannabinoid system can both improve and impair recognition of emotional faces.",
keywords = "Administration, Inhalation, Cannabidiol/pharmacology, Cross-Over Studies, Double-Blind Method, Dronabinol/pharmacology, Drug Combinations, Drug Interactions, Emotions/drug effects, Facial Recognition/drug effects, Female, Humans, Longitudinal Studies, Male, Marijuana Smoking/drug therapy, Photic Stimulation, Psychotropic Drugs/pharmacology, Schizotypal Personality Disorder/chemically induced, Surveys and Questionnaires, Visual Analog Scale, Young Adult",
author = "Chandni Hindocha and Freeman, {Tom P} and Grainne Schafer and Chelsea Gardener and Das, {Ravi K} and Morgan, {Celia J A} and Curran, {H Valerie}",
note = "Copyright {\circledC} 2014 The Authors. Published by Elsevier B.V. All rights reserved.",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.euroneuro.2014.11.014",
language = "English",
volume = "25",
pages = "325--334",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition

T2 - European Neuropsychopharmacology

AU - Hindocha, Chandni

AU - Freeman, Tom P

AU - Schafer, Grainne

AU - Gardener, Chelsea

AU - Das, Ravi K

AU - Morgan, Celia J A

AU - Curran, H Valerie

N1 - Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Acute administration of the primary psychoactive constituent of cannabis, Δ-9-tetrahydrocannabinol (THC), impairs human facial affect recognition, implicating the endocannabinoid system in emotional processing. Another main constituent of cannabis, cannabidiol (CBD), has seemingly opposite functional effects on the brain. This study aimed to determine the effects of THC and CBD, both alone and in combination on emotional facial affect recognition. 48 volunteers, selected for high and low frequency of cannabis use and schizotypy, were administered, THC (8mg), CBD (16mg), THC+CBD (8mg+16mg) and placebo, by inhalation, in a 4-way, double-blind, placebo-controlled crossover design. They completed an emotional facial affect recognition task including fearful, angry, happy, sad, surprise and disgust faces varying in intensity from 20% to 100%. A visual analogue scale (VAS) of feeling 'stoned' was also completed. In comparison to placebo, CBD improved emotional facial affect recognition at 60% emotional intensity; THC was detrimental to the recognition of ambiguous faces of 40% intensity. The combination of THC+CBD produced no impairment. Relative to placebo, both THC alone and combined THC+CBD equally increased feelings of being 'stoned'. CBD did not influence feelings of 'stoned'. No effects of frequency of use or schizotypy were found. In conclusion, CBD improves recognition of emotional facial affect and attenuates the impairment induced by THC. This is the first human study examining the effects of different cannabinoids on emotional processing. It provides preliminary evidence that different pharmacological agents acting upon the endocannabinoid system can both improve and impair recognition of emotional faces.

AB - Acute administration of the primary psychoactive constituent of cannabis, Δ-9-tetrahydrocannabinol (THC), impairs human facial affect recognition, implicating the endocannabinoid system in emotional processing. Another main constituent of cannabis, cannabidiol (CBD), has seemingly opposite functional effects on the brain. This study aimed to determine the effects of THC and CBD, both alone and in combination on emotional facial affect recognition. 48 volunteers, selected for high and low frequency of cannabis use and schizotypy, were administered, THC (8mg), CBD (16mg), THC+CBD (8mg+16mg) and placebo, by inhalation, in a 4-way, double-blind, placebo-controlled crossover design. They completed an emotional facial affect recognition task including fearful, angry, happy, sad, surprise and disgust faces varying in intensity from 20% to 100%. A visual analogue scale (VAS) of feeling 'stoned' was also completed. In comparison to placebo, CBD improved emotional facial affect recognition at 60% emotional intensity; THC was detrimental to the recognition of ambiguous faces of 40% intensity. The combination of THC+CBD produced no impairment. Relative to placebo, both THC alone and combined THC+CBD equally increased feelings of being 'stoned'. CBD did not influence feelings of 'stoned'. No effects of frequency of use or schizotypy were found. In conclusion, CBD improves recognition of emotional facial affect and attenuates the impairment induced by THC. This is the first human study examining the effects of different cannabinoids on emotional processing. It provides preliminary evidence that different pharmacological agents acting upon the endocannabinoid system can both improve and impair recognition of emotional faces.

KW - Administration, Inhalation

KW - Cannabidiol/pharmacology

KW - Cross-Over Studies

KW - Double-Blind Method

KW - Dronabinol/pharmacology

KW - Drug Combinations

KW - Drug Interactions

KW - Emotions/drug effects

KW - Facial Recognition/drug effects

KW - Female

KW - Humans

KW - Longitudinal Studies

KW - Male

KW - Marijuana Smoking/drug therapy

KW - Photic Stimulation

KW - Psychotropic Drugs/pharmacology

KW - Schizotypal Personality Disorder/chemically induced

KW - Surveys and Questionnaires

KW - Visual Analog Scale

KW - Young Adult

U2 - 10.1016/j.euroneuro.2014.11.014

DO - 10.1016/j.euroneuro.2014.11.014

M3 - Article

VL - 25

SP - 325

EP - 334

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 3

ER -